BARCLAYS PLC - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 69 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$39
-15.2%
50,0610.0%0.00%
Q2 2023$46
-100.0%
50,061
-85.3%
0.00%
Q3 2022$366,000
-14.9%
340,068
+34.6%
0.00%
Q2 2022$430,000252,682
+2297009.1%
0.00%
Q3 2021$011
-77.6%
0.00%
Q2 2021$0
-100.0%
49
-99.4%
0.00%
Q1 2021$43,0000.0%8,189
+2.5%
0.00%
Q4 2020$43,000
-27.1%
7,988
+7.9%
0.00%
Q3 2020$59,000
-20.3%
7,4000.0%0.00%
Q2 2020$74,000
+270.0%
7,4000.0%0.00%
Q1 2020$20,000
+1900.0%
7,400
+1306.8%
0.00%
Q4 2019$1,000
-50.0%
526
-68.0%
0.00%
Q3 2019$2,000
-50.0%
1,643
+88.6%
0.00%
Q1 2019$4,000
+100.0%
871
+221.4%
0.00%
Q4 2018$2,000
+100.0%
271
+367.2%
0.00%
Q3 2018$1,000
-99.8%
58
-99.8%
0.00%
Q2 2018$417,000
+3.5%
35,111
-2.3%
0.00%
Q1 2018$403,000
+72.2%
35,951
+2.4%
0.00%
Q4 2017$234,000
-24.0%
35,100
-6.6%
0.00%
Q3 2017$308,00037,6000.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q1 2019
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$2,341,0003.33%
Matrix Capital Management Company, LP 38,974,185$66,256,0001.50%
NEA Management Company, LLC 17,082,612$29,040,0001.49%
Endurant Capital Management LP 1,824,065$3,101,0001.09%
Long Focus Capital Management, LLC 4,679,491$7,955,0000.83%
Key Client Fiduciary Advisors, LLC 416,166$707,0000.69%
PFM Health Sciences, LP 9,109,780$15,487,0000.59%
ACT CAPITAL MANAGEMENT, LLC 90,000$153,0000.21%
DAFNA Capital Management LLC 351,064$597,0000.16%
Rock Springs Capital Management LP 2,357,544$4,008,0000.12%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders